MediWound Ltd.
NASDAQ:MDWDBiotechnology
-$0.09 today
- Market cap
- $176.61M
- Beta
- 0.15
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$2.03
Volume 0.16M
Average 0.09M
MDWD EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
MediWound Ltd.NASDAQ: MDWD
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.23, compared with -$0.07 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.26.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$1.99 (+5.1%) for the fiscal year ending Dec 2026, a slowdown from the +30.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.23+58.9% QoQ
- Last fiscal yearDec 2025
- -$2.1+30.7% YoY
- LTMMar 2026
- -$2.26-8.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -242.3% | +38.1% | +280.3 pp |
| 1 year | +30.7% | +5.1% | -25.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (2.10) USD
- Year-over-year change
- +30.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.10) | +30.7% |
| FY2024 | 2024-12-31 | (3.03) | -304.0% |
| FY2023 | 2023-12-31 | (0.75) | +80.9% |
| FY2022 | 2022-12-31 | (3.93) | -12.9% |
| FY2021 | 2021-12-31 | (3.48) | — |
EPS (Diluted) vs competitors
How MDWD compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -8.3% is the 6th highest of 9, against a peer median of +17.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | -$0.2 USD | +31.5% | — | |
| LTM Mar 2026 | -$0.37 USD | +68.8% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$1 USD | -29.9% | — |
| LTM Mar 2026 | -$1.42 USD | +19.8% | — | |
| LTM Mar 2026 | -$1.46 USD | +15.1% | — | |
| FY2025 | -€1.82 EUR | +48.6% | — | |
| LTM Mar 2026 | -$1.94 USD | — | — | |
| LTM Mar 2026 | -$2.26 USD | -8.3% | — | |
| LTM Mar 2026 | -$3.21 USD | -150.8% | — | |
| LTM Mar 2026 | -$5.7 USD | -325.7% | — | |
| Peer median (excluding MDWD) | — | +17.4% | — | |
Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.76M | 26.5M | 18.69M | 20.22M | 16.96M |
| Cost of Revenue | 14.99M | 13.33M | 15.11M | 17.59M | 13.71M |
| Gross Profit | 8.77M | 13.17M | 3.58M | 2.63M | 3.25M |
| Gross Margin | 36.9% | 49.7% | 19.1% | 13.0% | 19.2% |
| Research & Development | 10.26M | 10.18M | 7.47M | 8.88M | 14.32M |
| Selling, General & Admin | 9.45M | 10.37M | 11.38M | 12.91M | 13.93M |
| Operating Expenses | 19.99M | 20.83M | 19.08M | 22.02M | 28.53M |
| Depreciation & Amortization | 1.24M | 1.27M | 1.3M | 1.48M | 1.86M |
| EBITDA | (11.38M) | (18.25M) | (4.8M) | (27.93M) | (21.47M) |
| EBITDA Margin | -47.9% | -68.9% | -25.7% | -138.1% | -126.6% |
| Operating Income | (11.22M) | (7.66M) | (15.5M) | (19.38M) | (25.28M) |
| Operating Margin | -47.2% | -28.9% | -83.0% | -95.8% | -149.1% |
| Interest Income | 11K | 270K | 2.34M | 2.05M | 1.86M |
| Interest Expense | 167K | 162K | 335K | 561K | 663K |
| Other Income / Expenses | (2.3M) | (11.86M) | 8.97M | (10.78M) | 1.57M |
| Income Before Tax | (13.52M) | (19.52M) | (6.53M) | (30.16M) | (23.71M) |
| Pre-Tax Margin | -56.9% | -73.7% | -35.0% | -149.2% | -139.8% |
| Income Tax Expense | 27K | 78K | 185K | 61K | 169K |
| Net Income | (13.55M) | (19.6M) | (6.72M) | (30.22M) | (23.88M) |
| Net Margin | -57.0% | -74.0% | -35.9% | -149.5% | -140.8% |
| EPS (Basic) | (3.48) | (3.93) | (0.75) | (3.03) | (2.10) |
| EPS (Diluted) | (3.48) | (3.93) | (0.75) | (3.03) | (2.10) |
| Weighted Avg Shares | 3.89M | 4.99M | 9.01M | 9.96M | 11.38M |
| Weighted Avg Shares (Diluted) | 3.89M | 4.99M | 9.01M | 9.96M | 11.38M |
MediWound Ltd.
NASDAQ:MDWD
Intrinsic Alpha fair value
Locked
Current Price
$13.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.